Response and effectiveness
Top 6 in Top 7 Things to Know About Cosentyx
Cosentyx begins to work within a few weeks, but full effects may not be seen for up to four months.
After 12 weeks of taking Cosentyx 300mg, 77.1% of patients had a 75% reduction in their PASI (Psoriasis Area and Severity Index) score. After 16 weeks, this figure had risen to 86.7% of patients.
After 4 weeks, 50% of patients with psoriatic arthritis had an ACR 20 (this corresponds to a 20% improvement in psoriatic arthritis). By 16 weeks, 62.6% of psoriatic arthritis patients had reached ARC20, and 39.6% of patients had reached ARC50.
The FUTURE 5 study found that 91.8% of psoriatic arthritis patients taking Cosentyx 300mg experienced no radiographic disease progression over the course of 52 weeks.
It took 3 weeks for 50% of Ankylosing Spondylitis (AS) patients to achieve an ASAS20 (20% improvement in AS). At 3 weeks, the ASAS40 response was more than 20%, and by 16 weeks, the number of patients with an ASAS20 response had increased to 61.1%, while the number of patients with an ASAS40 response was 36.1%.
X-rays revealed that 79% of AS patients on long-term Cosentyx 150 mg therapy had no definite disease progression in the MEASURE 1 study.
By 16 weeks, 13% of patients with non-radiographic Axial Spondyloarthritis had a response of ASAS40 (40% improvement), which increased to 19% by week 52.
